Document Information


PMID 17241118  (  )
Title The CB2 cannabinoid agonist AM-1241 prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis when initiated at symptom onset.
Abstract Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease characterized by progressive motor neuron loss, paralysis and death within 2-5 years of diagnosis. Currently, no effective pharmacological agents exist for the treatment of this devastating disease. Neuroinflammation may accelerate the progression of ALS. Cannabinoids produce anti-inflammatory actions via cannabinoid receptor 1 (CB1) and cannabinoid receptor 2 (CB2), and delay the progression of neuroinflammatory diseases. Additionally, CB2 receptors, which normally exist primarily in the periphery, are dramatically up-regulated in inflamed neural tissues associated with CNS disorders. In G93A-SOD1 mutant mice, the most well-characterized animal model of ALS, endogenous cannabinoids are elevated in spinal cords of symptomatic mice. Furthermore, treatment with non-selective cannabinoid partial agonists prior to, or upon, symptom appearance minimally delays disease onset and prolongs survival through undefined mechanisms. We demonstrate that mRNA, receptor binding and function of CB2, but not CB1, receptors are dramatically and selectively up-regulated in spinal cords of G93A-SOD1 mice in a temporal pattern paralleling disease progression. More importantly, daily injections of the selective CB2 agonist AM-1241, initiated at symptom onset, increase the survival interval after disease onset by 56%. Therefore, CB2 agonists may slow motor neuron degeneration and preserve motor function, and represent a novel therapeutic modality for treatment of ALS. of Arkansas for Medical Sciences, Little Rock, Arkansas 72205, USA.

NOTE: Color highlight is limited to the abstract and SciMiner text-mining mode. If you see much more identified targets below from "Targets by SciMiner Summary" and "Targets by SciMiner Full list", they may have been identified from the full text.



Targets by SciMiner Summary

HUGO ID Symbol Target Name #Occur ActualStr
2160CNR2cannabinoid receptor 2 (macrophage)7CB2 | cannabinoid receptor 2 |
2159CNR1cannabinoid receptor 1 (brain)3cannabinoid receptor 1 | CB1 |

 


Targets by SciMiner Full list

HUGO ID Symbol Name ActualStr Score FlankingText
2160CNR2cannabinoid receptor 2 (macrophage)CB20.9The CB2 cannabinoid agonist AM-1241 prolongs survival in a transgenic mouse model
2159CNR1cannabinoid receptor 1 (brain)CB10.9Cannabinoids produce anti-inflammatory actions via cannabinoid receptor 1 (CB1) CB1 and cannabinoid receptor 2 (CB2), CB2 and delay the progression
2160CNR2cannabinoid receptor 2 (macrophage)CB20.9cannabinoid receptor 1 (CB1) CB1 and cannabinoid receptor 2 (CB2), CB2 and delay the progression of neuroinflammatory diseases
2160CNR2cannabinoid receptor 2 (macrophage)CB20.9Additionally CB2 receptors which normally exist primarily in the periphery are dramatically
2160CNR2cannabinoid receptor 2 (macrophage)CB20.9We demonstrate that mRNA receptor binding and function of CB2 but not CB1 receptors are dramatically and selectively up-regulated in
2159CNR1cannabinoid receptor 1 (brain)CB10.9that mRNA receptor binding and function of CB2 but not CB1 receptors are dramatically and selectively up-regulated in spinal cords of
2160CNR2cannabinoid receptor 2 (macrophage)CB20.9More importantly daily injections of the selective CB2 agonist AM-1241 initiated at symptom onset increase the survival interval
2160CNR2cannabinoid receptor 2 (macrophage)CB20.9Therefore CB2 agonists may slow motor neuron degeneration and preserve motor function
2159CNR1cannabinoid receptor 1 (brain)cannabinoid receptor 11.0cannabinoids produce anti inflammatory actions via cannabinoid receptor 1 cb1 and cannabinoid receptor 2 cb2 and delay the progression of neuroinflammatory diseases.
2160CNR2cannabinoid receptor 2 (macrophage)cannabinoid receptor 21.0cannabinoids produce anti inflammatory actions via cannabinoid receptor 1 cb1 and cannabinoid receptor 2 cb2 and delay the progression of neuroinflammatory diseases.